Cargando…

Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy

Peptide receptor radioligand therapy (PRRT) was Food and Drug Administration approved in 2018 for the treatment of unresectable somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) and provides an important option for patients with advanced disease. A known adverse effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naveed Ahmad, Junid A., Schroeder, Brett B., Ruhoy, Steven M., Kennecke, Hagen F., Lin, Bruce S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983945/ https://www.ncbi.nlm.nih.gov/pubmed/35307721 http://dx.doi.org/10.1097/RLU.0000000000004130

Ejemplares similares

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2023)

Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
por: Naveed Ahmad, Junid A., et al.
Publicado: (2023)

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms
por: Iravani, Amir, et al.
Publicado: (2022)

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases
por: Loree, Jonathan M., et al.
Publicado: (2016)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms
por: Malandrino, Pasqualino, et al.
Publicado: (2022)

Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
por: Al-Efraij, Khalid, et al.
Publicado: (2015)

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
por: Capdevila, Jaume, et al.
Publicado: (2022)

Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review
por: Urso, Luca, et al.
Publicado: (2022)

Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
por: Saracyn, Marek, et al.
Publicado: (2022)

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
por: Puranik, Ameya D, et al.
Publicado: (2021)

Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration
por: Segelov, Eva, et al.
Publicado: (2016)

Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors—Extended Analysis of Potential Acute and Chronic Complications
por: Saracyn, Marek, et al.
Publicado: (2023)

[(212)Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
por: Chapeau, Dylan, et al.
Publicado: (2023)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
por: Kumar, Amit, et al.
Publicado: (2022)

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT
por: Tsang, Erica S., et al.
Publicado: (2021)

Editorial: Response assessment of radioligand therapies
por: Lopci, Egesta, et al.
Publicado: (2022)

Radioligand saturation binding for quantitative analysis of ligand-receptor interactions
por: Dong, Chengyan, et al.
Publicado: (2016)

Optimum Conditions of Radioligand Receptor Binding Assay of Ligands of Benzodiazepine Receptors
por: Ahmadi, Fatemeh, et al.
Publicado: (2014)

Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases
por: Tsang, Erica S., et al.
Publicado: (2020)

Synthesis and Investigation of a Radioiodinated F3 Peptide Analog as a SPECT Tumor Imaging Radioligand
por: Bhojani, Mahaveer S., et al.
Publicado: (2011)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Commercial and business aspects of alpha radioligand therapeutics
por: Ostuni, Emanuele, et al.
Publicado: (2023)

Kidney Protection with the Radical Scavenger α(1)-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy
por: Kristiansson, Amanda, et al.
Publicado: (2021)

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
por: Anwer, Faiz, et al.
Publicado: (2015)

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
por: Schirrmacher, Ralf, et al.
Publicado: (2019)

Patterns of Practice and Improvements in Survival Among Patients With Stage 2/3 Rectal Cancer Treated With Trimodality Therapy
por: Kennecke, Hagen F., et al.
Publicado: (2022)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care
por: Del Rivero, Jaydira, et al.
Publicado: (2023)

Radioligand Assay-Based Detection of Antibodies against SARS-CoV-2 in Hospital Workers Treating Patients with Severe COVID-19 in Japan
por: Matsunaga, Hidenori, et al.
Publicado: (2021)

Glucose Metabolism Modification Induced by Radioligand Therapy with [(177)Lu]Lu/[(90)Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
por: Urso, Luca, et al.
Publicado: (2022)

The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation
por: Dudani, Shaan, et al.
Publicado: (2021)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Radioligand therapies in cancer: mapping the educational landscape in Europe
por: Bugani, Valentina, et al.
Publicado: (2023)

Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.
por: Helin, H., et al.
Publicado: (1990)

A radioligand binding assay for the insulin-like growth factor 2 receptor
por: Potalitsyn, Pavlo, et al.
Publicado: (2020)

Challenges of Caring for an Advanced Chronic Kidney Disease Patient with Severe Thrombocytopenia
por: Akimoto, Tetsu, et al.
Publicado: (2013)

Proteomics-based diagnostic peptide discovery for severe fever with thrombocytopenia syndrome virus in patients
por: Lee, Sang-Yeop, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m5u8nqdt0ka50s1jpdch4shhnl